The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan
Crossref DOI link:
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/SPRINGER_CROSSMARK_POLICY
Cornelius, Victoria R.
Funding for this research was provided by:
Efficacy and Mechanism Evaluation Programme (11/14/24)